Abiopharma

🔍 DUCHENE TODD M (Executive)

Company: Core Scientific, Inc./tx (CORZ)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 216,734 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: A | equity_swap_involved: false | shares_owned_after: 2,154,741.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 97,652 shares of Common Stock at $14.96 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: false | shares_owned_after: 2,057,089.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 10,000 shares of Common Stock at $15.2523 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: false | shares_owned_after: 2,047,089.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Represents a performance-based restricted stock unit ("PSU") grant. The Reporting Person was granted PSUs on April 28, 2025 that vest based on the satisfaction of specified performance criteria, provided that the Reporting Person continues to provide service to the Issuer through the end of the applicable measurement period. Effective as of March 31, 2026, in accordance with the terms of the applicable PSUs, the Compensation Committee of the Board of Directors of the Issuer certified the level of satisfaction of the applicable prescribed performance criteria and approved the settlement of such PSUs.
• F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
• F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• REMARKS: Chief Legal and Administrative Officer